Nuformix plc (LON:NFX – Get Free Report) traded up 10% during mid-day trading on Wednesday. The company traded as high as GBX 0.11 and last traded at GBX 0.11. 12,136,803 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 28,948,861 shares. The stock had previously closed at GBX 0.10.
Nuformix Stock Performance
The stock’s fifty day simple moving average is GBX 0.14 and its 200-day simple moving average is GBX 0.16. The stock has a market cap of £2.48 million, a P/E ratio of -3.24 and a beta of 1.53.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Further Reading
- Five stocks we like better than Nuformix
- Microsoft’s Earnings Problem: Even Great May Not Be Enough
- 3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
